Physician profile
Stephani Brooke Brisbin
NPI 1487151106
$588.33
in general payments reported to CMS, 2019-2025
13 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $76.75 · 2024: $283 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.09 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.11 | 2023-2024 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $59.11 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $50.74 | 2024 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $50.37 | 2024-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $45.27 | 2023-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $34.87 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Lilly USA, LLC | $30.74 | 2024-2025 | Zepbound, Mounjaro, Trulicity |
| Corium, LLC | $30.62 | 2023 | Azstarys |
| Lundbeck LLC | $22.16 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $15.83 | 2025 | Gemtesa |
| Pfizer INC. | $15.47 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.95 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephani Brisbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.